Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 4/20 | 0.53 |
| ▸ | MIF | P14174 | 3/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963676 | 0.91 | NOTUM (0.59) | DDX3XMIFNOTUMFOLH1MAOA | |
| SCHEMBL19976445 | 0.87 | MIF (0.53) | DDX3XMIFNOTUMFOLH1MAOA | |
| SCHEMBL16964548 | 0.87 | DDX3X (0.56) | DDX3XMIFFOLH1RAB9ASMN1; SMN2 | |
| SCHEMBL16991070 | 0.86 | MIF (0.52) | DDX3XMIFNOTUMFOLH1MAOA | |
| SCHEMBL19976510 | 0.85 | FOLH1 (0.47) | DDX3XMIFFOLH1 | |
| SCHEMBL16964675 | 0.84 | MIF (0.50) | DDX3XMIFNOTUMFOLH1MAOA | |
| SCHEMBL19976444 | 0.82 | MIF (0.46) | MIFOPRD1P2RY14SIGMAR1GAA | |
| SCHEMBL17000543 | 0.81 | MIF (0.48) | MIFMAOAMAOBOPRD1P2RY14 | |
| SCHEMBL16964165 | 0.81 | MIF (0.46) | MIFFOLH1OPRD1P2RY14SIGMAR1 | |
| SCHEMBL16964139 | 0.80 | AR (0.46) | MIFOPRD1P2RY14SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | claimed |
| EP-2900638-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | Université de Droit et de la Santé de Lille 2 (FR) | 2015-08-05 | — | — | EP | claimed |
| US-9920042-B2 | Compounds for use in the treatment of mycobacterial infections | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-03-20 | — | — | US | disclosed |
| US-9920042-B2 | Compounds for use in the treatment of mycobacterial infections | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-03-20 | — | — | US | disclosed |
| US-9920042-B2 | Compounds for use in the treatment of mycobacterial infections | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-03-20 | — | — | US | disclosed |
| EP-2900638-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 (FR) | 2017-01-04 | — | — | EP | disclosed |
| EP-2900638-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | disclosed |
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | disclosed |
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | disclosed |
| EP-2900638-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | Université de Droit et de la Santé de Lille 2 (FR) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | C5, ALK, TYR | DDX3X 4557/4885MIF 2773/4885NOTUM 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.